Cognitive Impairment in Ageing People
1 other identifier
observational
5,000
1 country
1
Brief Summary
Mild cognitive impairment (MCI) and neurocognitive disorder such as Alzheimer's disease (AD) and Vascular dementia (VaD) have become common diseases in the elderly. The burden of dementia is rising in China, with major medical, social and economic impacts. To address this important public health problem, cohort study on elderly cognitive disorders should be carry out. The methods of early prevention, early diagnosis and early treatment the cognitive disorders in elderly should be found to reduce the burden of the social and economic issue due to dementia. At present, the international corresponding guidelines have taken gene and brain imaging biomarkers as important indicators of dementia pathogenesis research, accurate diagnosis and targeted intervention. The study will construct a prospective cohort to establish database that provide not only comprehensive epidemiological data on the MCI and neurocognitive disorder in ageing people, but also complete the construction of biological samples bank and clinical diagnosis and treatment information database. Using the database, the study will identify the conversion rates from MCI to dementia and risk factors for the progression from MCI to dementia or AD. The study will also apply and develop brain structural and pathological imaging technology to support precision diagnosis of senile cognitive disorders. The study have goals to identify and validate imaging and blood/CSF biomarkers for the early detection and tracking of cognitive disorders.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2020
CompletedFirst Submitted
Initial submission to the registry
April 12, 2020
CompletedFirst Posted
Study publicly available on registry
April 24, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2040
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2040
September 14, 2020
September 1, 2020
20.7 years
April 12, 2020
September 11, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Incidence of Dementia
April 2020 to December 2040
Secondary Outcomes (2)
The conversion rate of normal elderly to MCI to neurocognitive disorder
April 2020 to December 2040
Improvement of Cognitive Function based on Montreal Cognitive Assessment (MoCA) score
April 2020 to December 2040
Study Arms (2)
Normal Aging
Normal Aging with normal cognitive function
Mild cognitive impairment (MCI)
Mild cognitive impairment subjects with memory loss as predominant symptom
Eligibility Criteria
Adult Chinese aged 50 and up, receiving outpatient or inpatient service of Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University.
You may qualify if:
- Patients over 50 years old.
- Sign informed consent.
- According to DSM-IV, the diagnostic standard of dementia was not met.
- The clinical dementia rating (CDR) was 0.5.
You may not qualify if:
- Subjects with mental retardation.
- Refuse to have blood sampling, imaging and other examinations.
- Uncooperative subjects that have serious organic diseases, or have a history of mental illness, or have physical disability (including severe aphasia).
- Contraindications of MR scanning.
- Suffering from serious physical or mental illness.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Yamei Tanglead
Study Sites (1)
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510120, China
Related Publications (1)
Zhu Y, Pan D, He L, Rong X, Li H, Li Y, Pi Y, Xu Y, Tang Y. China Registry Study on Cognitive Impairment in the Elderly: Protocol of a Prospective Cohort Study. Front Aging Neurosci. 2021 Dec 23;13:797704. doi: 10.3389/fnagi.2021.797704. eCollection 2021.
PMID: 35002683DERIVED
Biospecimen
Humoral biomarkers in plasma, cerebrospinal fluid, stool, and urine
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 12, 2020
First Posted
April 24, 2020
Study Start
April 1, 2020
Primary Completion (Estimated)
December 1, 2040
Study Completion (Estimated)
December 1, 2040
Last Updated
September 14, 2020
Record last verified: 2020-09